EGFR expression is linked to osteopontin and Nf-κB signaling in clear cell renal cell carcinoma

Clinical and Translational Oncology

Volumn 15, Issue 1, 2013, Pages 65-71

  Matusan Ilijas K ^a   Damante, G ^b   Fabbro, D ^c   Dordevic G ^a   Hadzisejdic I ^a   Grahovac, M ^d   Avirovic M ^a   Grahovac, B ^a   Jonjic N ^a   Lucin K ^a  

^a UNIVERSITY OF RIJEKA   (Croatia)

^b UNIVERSITY OF UDINE   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

EGFR; Nuclear factor kappa B; Osteopontin; Renal cell carcinoma; Tissue array analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOPONTIN;

ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; KIDNEY CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UPREGULATION;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; NF-KAPPA B; OSTEOPONTIN; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84872418300     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0889-9     Document Type: Article

References (36)

1. Wells A (1999) EGF receptor. Int J Biochem Cell Biol 31:637-643
2. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8:11-31
3. Lu Z, Jiang G, Blume-Jensen P, Hunter T (2001) Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol 21:4016-4031
4. Goel S, Hidalgo M, Perez-Soler R (2007) EGFR inhibitor-mediated apoptosis in solid tumors. J Exp Ther Oncol 6:305-320
5. Wheeler DL, Dunn EF, Harari PM (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7:493-507
6. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2-16
7. Streuli CH, Akhtar N (2009) Signal co-operation between integrins and other receptor systems. Biochem J 418:491-506
8. Cabodi S, del Pilar Camacho-Leal M, Di Stefano P, Defilippi P (2010) Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer 10:858-870
9. Rittling SR, Chambers AF (2008) Role of osteopontin in tumour progression. Br J Cancer 90:1877-1881
10. Wai PY, Kuo PC (2008) Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27:103-118
11. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184-190
12. Standal T, Borset M, Sundan A (2004) Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26:179-184
13. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS (2006) The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 6:463-474
14. Tuck AB, Hota C, Wilson SM, Chambers AF (2003) Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 22:1198-1205
15. Philip S, Bulbule A, Kundu GC (2001) Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 276:44926-44935
16. Matusan K, Dordevic G, Stipic D, Mozetic V, Lucin K (2006) Osteopontin expression correlates with prognostic variables and survival in clear cell renal-cell carcinoma. J Surg Oncol 4:325-331
17. Matušan-Ilijaš K, Damante G, Fabbro D, Dordević G, Hadžisejdić I, Grahovac M, Marić I, Španjol J, Grahovac B, Jonjić N, Lučin K (2011) Osteopontin expression correlates with nuclear factor-kappa B activation and apoptosis downregulation in clear cell renal cell carcinoma. Pathol Res Pract 207:104-110
18. Zhang G, He B, Weber GF (2003) Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer. Mol Cell Biol 23:6507-6519
19. Malyankar UM, Almeida M, Johnson RJ, Pichler RH, Giachelli CM (1997) Osteopontin regulation in cultured rat renal epithelial cells. Kidney Int 51:1766-1773
20. Zhang G, Zhao ZQ, Wang HD, Hao B (2004) Enhancement of osteopontin expression in HepG2 cells by epidermal growth factor via phosphatidylinositol 3-kinase signaling pathway. World J Gastroenterol 10:205-208
21. Chakalaparampil I, Peri A, Nemir M, Mckee MD, Lin PH, Mukherjee BB, Mukherjee AB (1996) Cells in vivo and in vitro from osteopetrotic mice homozygous for c-src disruption show suppression of synthesis of osteopontin, a multifunctional extracellular matrix protein. Oncogene 12:1457-1467
22. Ivaska J, Heino J (2010) Interplay between cell adhesion and growth factor receptors: from the plasma membrane to the endosomes. Cell Tissue Res 339:111-120
23. Angelluci A, Festuccia C, Gravina GL, Muzi P, Bonghi L, Vicentini C, Bologna M (2004) Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate 59:157-166
24. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R (2004) Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation? J Clin Pathol 57:773-775
25. Kallio JP, Hirvikoski P, Helin H, Kellokumpu-Lehtinen P, Luukkaala T, Tammela TL, Martikainen PM (2003) Membranous location of EGFR immunostaining is associated with good prognosis in renal cell carcinoma. Br J Cancer 89:1266-1269
26. Pu YS, Huang CY, Kuo YZ, Kang WY, Liu GY, Huang AM, Yu HJ, Lai MK, Huang SP, Wu WJ, Chiou SJ, Hour TC (2009) Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma. J Biomed Sci 16:82
27. Merseburger AS, Hennenlotter J, Simon P, Kruck S, Koch E, Horstmann M, Kuehs U, Küfer R, Stenzl A, Kuczyk MA (2005) Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. Anticancer Res 3:1901-1907
28. Piazzi G, Paterini P, Ceccarelli C, Pantaleo MA, Biasco G (2006) Molecular determination of epidermal growth factor receptor in normal and neoplastic colorectal mucosa. Br J Cancer 95:1525-1528
29. Keese M, Magdeburg RJ, Herzog T, Hasenberg T, Offterdinger M, Pepperkok R, Sturm JW, Bastiaens PI (2005) Imaging epidermal growth factor receptor phosphorylation in human colorectal cancer cells and human tissues. J Biol Chem 280:27826-27831
30. Nannini M, Pantaleo MA, Paterini P, Piazzi G, Ceccarelli C, La Rovere S, Maleddu A, Biasco G (2011) Molecular detection of epidermal growth factor receptor in colorectal cancer: does it still make sense? Colorectal Dis 5:542-548. doi: 10.1111/j.1463-1318.2010.02212.x
31. Dei Tos AP, Ellis I (2005) Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? Eur J Cancer 41:1383-1392
32. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 25(29):4536-4541
33. Jermann M, Stahel RA, Salzberg M, Cerny T, Joerger M, Gillessen S, Morant R, Egli F, Rhyner K, Bauer JA, Pless M (2006) A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol 57:533-539
34. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A (2005) Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23:7889-7896
35. Ravaud A, Hawkins R, Gardner JP, von der Maase H, Zantl N, Harper P, Rolland F, Audhuy B, Machiels JP, Pétavy F, Gore M, Schöffski P, El-Hariry I (2008) Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 26:2285-2291
36. Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P, Sebastiani V, Maitra A, Hidalgo M (2005) Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 65:3003-3010